Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review

Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology. MEDLINE, CINAHL, P...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:EClinicalMedicine Ročník 53; s. 101624
Hlavní autoři: Notarte, Kin Israel, Catahay, Jesus Alfonso, Velasco, Jacqueline Veronica, Pastrana, Adriel, Ver, Abbygail Therese, Pangilinan, Flos Carmeli, Peligro, Princess Juneire, Casimiro, Michael, Guerrero, Jonathan Jaime, Gellaco, Ma. Margarita Leticia, Lippi, Giuseppe, Henry, Brandon Michael, Fernández-de-las-Peñas, César
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Elsevier Ltd 01.11.2022
Elsevier
Témata:
Internal Medicine
Long-COVID symptoms
Post-COVID syndrome
SARS-CoV-2
Vaccine
Long-COVID symptoms
SARS-CoV-2
Vaccine
Post-COVID syndrome
ISSN:2589-5370, 2589-5370
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology. MEDLINE, CINAHL, PubMed, EMBASE, and Web of Science databases, as well as medRxiv and bioRxiv preprint servers were searched up to June 20, 2022. Peer-reviewed studies or preprints monitoring multiple symptoms appearing after acute SARS-CoV-2 infection either before or after COVID-19 vaccination collected by personal, telephone or electronic interviews were included. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale. From 2584 studies identified, 11 peer-reviewed studies and six preprints were included. The methodological quality of 82% (n=14/17) studies was high. Six studies (n=17,256,654 individuals) investigated the impact of vaccines before acute SARS-CoV-2 infection (vaccine-infection-long-COVID design). Overall, vaccination was associated with reduced risks or odds of long-COVID, with preliminary evidence suggesting that two doses are more effective than one dose. Eleven studies (n=36,736 COVID-19 survivors) investigated changes in long-COVID symptoms after vaccination (infection-long-COVID-vaccine design). Seven articles showed an improvement in long-COVID symptoms at least one dose post-vaccination, while four studies reported no change or worsening in long-COVID symptoms after vaccination. Low level of evidence (grade III, case-controls, cohort studies) suggests that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID. The impact of vaccination in people with existing long-COVID symptoms is still controversial, with some data showing changes in symptoms and others did not. These assumptions are limited to those vaccines used in the studies. The LONG-COVID-EXP-CM study supported by a grant of Comunidad de Madrid.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2589-5370
2589-5370
DOI:10.1016/j.eclinm.2022.101624